The BIOVF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOVF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BIOVF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BIOVF Detailed Price Forecast - CNN Money||View BIOVF Detailed Summary - Google Finance|
|View BIOVF Detailed Summary - Yahoo! Finance||View BIOVF Stock Research & Analysis - Zacks.com|
|View BIOVF Trends & Analysis - Trade-Ideas||View BIOVF Major Holders - Barrons|
|View BIOVF Call Transcripts - NASDAQ||View BIOVF Breaking News & Analysis - Seeking Alpha|
|View BIOVF Annual Report - CompanySpotlight.com||View BIOVF OTC Short Report - OTCShortReport.com|
|View BIOVF Fundamentals - TradeKing||View BIOVF SEC Filings - Bar Chart|
|View Historical Prices for BIOVF - The WSJ||View Performance/Total Return for BIOVF - Morningstar|
|View the Analyst Estimates for BIOVF - MarketWatch||View the Earnings History for BIOVF - CNBC|
|View the BIOVF Earnings - StockMarketWatch||View BIOVF Buy or Sell Recommendations - MacroAxis|
|View the BIOVF Bullish Patterns - American Bulls||View BIOVF Short Pain Metrics - ShortPainBot.com|
|View BIOVF Stock Mentions - StockTwits||View BIOVF Stock Mentions - PennyStockTweets|
|View BIOVF Stock Mentions - Twitter||View BIOVF Investment Forum News - Investor Hub|
|View BIOVF Stock Mentions - Yahoo! Message Board||View BIOVF Stock Mentions - Seeking Alpha|
|View Insider Transactions for BIOVF - SECform4.com||View Insider Transactions for BIOVF - Insider Cow|
|View BIOVF Major Holdings Summary - CNBC||View Insider Disclosure for BIOVF - OTC Markets|
|View Insider Transactions for BIOVF - Yahoo! Finance||View Institutional Holdings for BIOVF - NASDAQ|
|View BIOVF Stock Insight & Charts - FinViz.com||View BIOVF Investment Charts - StockCharts.com|
|View BIOVF Stock Overview & Charts - BarChart||View BIOVF User Generated Charts - Trading View|
STOCKHOLM, March 25, 2019 /PRNewswire/ -- Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the US Food and Drug Administration (FDA) approval in November 2018 of Gamifant® (emapalumab-lzsg) for the treatment of paediatric (newborn and older) and adult patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The Rare Impact Awards recognise individuals, organisations and industry innovators for outstanding work in support of the rare disease community.
Invitation to Sobi Capital Markets Day 14 May 2019
Posted on Thursday February 21, 2019
The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. The Capital Markets Day will be an opportunity for institutional investors, analysts and media to learn more about Sobi, our therapeutic areas and future growth strategy as well our financial performance. The agenda and more detailed information about the event will be published on Sobi's website closer to the event.
Sobi Presents Comprehensive Study Data on Extended Half-life Haemophilia Treatments at EAHAD
Posted on Thursday February 07, 2019
STOCKHOLM, Feb. 7, 2019 /PRNewswire/ -- Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February 2019, showing evidence on the safety, efficacy and long-term benefits of its extended half-life products for the treatment of haemophilia. The studies that will be presented support Sobi's commitment to develop a treatment paradigm that expand the possibilities and transform life for people with haemophilia. Sobi and our collaboration partner Sanofi will provide interim data on the incidence of inhibitors in previously untreated patients (PUPs) with severe haemophilia A treated with factor VIII Fc fusion protein (Elocta®): the PUPs A-LONG study.
Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
Posted on Monday November 12, 2018
STOCKHOLM, Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares.